Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas-Reference-Cited by-同舟云学术

Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas

Published:2023-05-19 Issue:2 Volume:129 Page:291-300
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Raj Nitya^ORCID,Chan Jennifer A.,Wang Stephanie J.,Aggarwal Rahul R.^ORCID,Calabrese Susan,DeMore April,Fong Lawrence,Grabowsky Jennifer,Hope Thomas A.,Kolli Kanti Pallav,Mulvey Claire K.,Munster Pamela N.,Perez Kimberly,Punn Sippy,Reidy-Lagunes Diane,Von Fedak Sofia,Zhang Li,Bergsland Emily K.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-023-02298-8.pdf

Reference65 articles.

1. Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases. Cancer. 2018;124:807–15.

2. Shia J, Tang LH, Weiser MR, Brenner B, Adsay NV, Stelow EB, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol. 2008;32:719–31.

3. Volante M, Birocco N, Gatti G, Duregon E, Lorizzo K, Fazio N, et al. Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. Hum Pathol. 2014;45:665–73.

4. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–12.

5. Smith J, Reidy-Lagunes D. The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas. Semin Oncol. 2013;40:100–8.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives;Cancers;2024-05-27

2. Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma;Cancers;2023-10-11

3. Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms;Current Oncology;2023-09-21